sur Immunic AG
Immunic to Attend Key Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company focusing on novel oral therapies for neurologic diseases, will participate in significant conferences this May. The company will attend the 26th Bio€quity Europe in Prague from May 4-6 and 12-13, where CEO Daniel Vitt and VP of Investor Relations Jessica Breu will conduct one-on-one meetings. Additionally, Immunic will be present at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte from May 27-29, presenting three posters on their ongoing research.
Highlights include a late-breaking poster on multiple sclerosis' neuroprotective effects by James Myles, Global Head of Biostatistics. Other presentations will cover the effects and safety of vidofludimus calcium from the Phase 2 CALLIPER trial. The company's participation underscores its commitment to advancing research in neurologic diseases.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG